Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clover Health Investments

Walgreens

For many investors, the concept of putting money into healthcare stocks to sell them at a future date might seem like a safe investment. After all, almost every person in the United States is dependent upon the corporatized healthcare system in some way or another.

3 Healthcare Stocks to Sell in May Before They Crash & Burn

Academy Sports and Outdoors

3D Systems

DDD, ASO and CVS have been added to the Zacks Rank #5 (Strong Sell) List on May 6, 2024.

New Strong Sell Stocks for May 6th

Dollar General

Estee Lauder

Gambling.com Group

Grab Holdings Ltd

Sandstorm Gold

Prosus NV

Investors have been fearful of a market crash. As such, they ended up dumping several stocks.

The 7 Most Undervalued Stocks to Buy Now: Q2 Edition

Prudential Financial

Prudential Financial has earned its reputation as a rock-solid insurer. Berkshire Hathaway has shown itself as a master of investing the float.

3 Insurance Stocks That Could Make You a Millionaire

LOS ANGELES, CA / ACCESSWIRE / May 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CVS Health Corporation and Encourages Investors to Contact the Firm

CVS Health reported dismal earnings on May 1st, substantially dropping the stock price, resulting in the largest one-day drop on record. While revenues nearly met consensus expectations, current quarter EPS and forward earnings were slashed, roughly by the same amount as the stock price. The decline has been fairly orderly and an immediate bounce in the stock price is not expected.

CVS Health: A Terrible Earnings Report, But An Undervalued Stock

Ares Capital

Pfizer

Above-average utilization of health benefits pressured CVS Health's bottom line, but this is a temporary problem. Ares Capital is a business development company that offers a huge dividend yield at recent prices.

3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade

Shares in the drug chain and health insurer lost 19% after missing earnings and slashing guidance. The culprit: Costs for its Medicare Advantage plans.

CVS Stock Discovers a Medicare Disadvantage

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of CVS Health Corporation (“CVS” or the “Company”) (NYSE: CVS) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your CVS investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of CVS Health Corporation (CVS) on Behalf of Investors

CVS Health (NYSE: CVS) recently reported its Q1 results, with revenues and earnings missing our estimates. The company reported revenue of $88.4 billion and adjusted earnings of $1.31 per share, much lower than our estimates of $90 billion and $1.74, respectively.

Should You Pick CVS Health Stock At $55 After Q1 Miss?

Enterprise Products Partners

Kinder Morgan

MPLX

Williams

Earnings season presents buying opportunities for stocks that have experienced a dip in price after reporting Q1 earnings. Enterprise Products Partners offers a 7% yield and has strong fundamentals, including a well-covered distribution and positive outlook. CVS Health has a 5% yield and has been punished for higher medical utilization, but its pharmacy business is producing steadily growing results.

I'm Buying The Dip With Up To 7% Yield

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of CVS Health Corporation (“CVS” or the “Company”) (NYSE: CVS) investors concerning the Company's possible violations of federal securities laws. On May 1, 2024, CVS released its first quarter 2024 financial results, stating that adjusted earnings for the year would be approximately $7 a share, down from previous expectations of at least $8.30. Additionally, the Company lowered its forecast for c.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of CVS Health Corporation (CVS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of CVS Health Corporation (“CVS” or the “Company”) (NYSE: CVS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On May 1, 2024, CVS released its first quarter 2024 financial results, stating that adjusted earnings for the year would be approximately $7 a share, down from previous expectat.

The Law Offices of Frank R. Cruz Announces Investigation of CVS Health Corporation (CVS) on Behalf of Investors

CVS Health Corp (NYSE:CVS) copped a downgrade from buy to neutral from UBS today after the US pharmacy chain downwardly revised its full-year profit 2024 guidance amid rising medical costs in its Medicare insurance business.   In a full-year profit forecast published on Wednesday, the chain said it expects to report adjusted earnings per share (EPS) of around $7 compared to prior guidance of at least $8.30.

CVS downgraded after floundering in the first quarter

Baker Hughes Co

Dow Inc

Energy Transfer LP Unit

Ford Motor Company

Home Depot

MetLife

Omnicom Group

Philip Morris

Southern Company

Sysco

Verizon

The Summer 2023 edition of Fortune Magazine revealed the 500 biggest U.S. companies by revenue. Dogcatcher's quest to sniff out the best dividend buys focused on 68 industry leaders. Those 68 industry leaders were segmented into 21 business sectors, ranging (alphabetically) from apparel to wholesalers. 3 of the 68 were private or foreign-exchange listed firms, leaving 65 listed. 58 dividend-yielding stocks led those 68 industry leaders and ranged from 0.14% to 8.07% in annual yield and ranged -from 0.89% to 36.96% in broker-estimated one-year target-price upsides.

4 Fortune 500 Industry Leaders Boast Ideal April/May Dividends

Major U.S. equities indexes were mixed as the Federal Open Market Committee (FOMC) wrapped up its latest policy meeting, announcing it would maintain the federal funds rate at the decades-long high where it has remained since last July.

S&P 500 Gains and Losses Today: CVS Falls as Health Care Costs Pressure Profits

The volatile consumer healthcare sector showed up big in CVS' Q1 earnings Wednesday (May 1), with solid revenue from its store operations but a warning about revenue projections due to its foray into the insurance sector.  By the numbers, CVS Health reported first-quarter revenues of approximately $88 billion, marking a 4% increase year-over-year.

CVS Q1 Earnings Take A Hit From Insurance Venture

Adjusted EPS missed expectations significantly at $1.31 versus the forecasted $1.69. Revenue saw a year-over-year increase, albeit below analyst estimates.

CVS Health's Q1 Disappointed on Multiple Levels

Amazon

Walmart

Walmart Inc. WMT, -0.43% announced Tuesday it's closing its 51 health centers after the retail giant admitted the business had not seen sustainable profits since its inception in 2019.

Walmart is closing down its health centers. What's that mean for Amazon, Walgreens and CVS?

CVS Health Corp (NYSE:CVS) shares tanked after the pharmacy chain downwardly revised its full-year profit 2024 guidance amid rising medical costs in its Medicare insurance business.   The company is now expected to report adjusted earnings per share (EPS) of at least $7, down from its prior guidance of at least $8.30 and below the Wall Street estimate of $8.31.

CVS slashes full-year profit forecast on elevated medical costs; shares plunge

CVS faced higher-than-expected costs in its insurance business. Lower Medicare Advantage reimbursement rates are expected to weigh on its performance.

Why CVS Health Stock Plunged Today

CVS Health's (CVS) Q1 performance is impacted by a decline in the Health Services segment due to continued pharmacy client price improvements.

CVS Health's (CVS) Q1 Earnings Miss Estimates, Margins Up

CVS Health came up short of Q1 earnings estimates and slashed its full-year outlook as medical costs surged. Here's what you need to know.

CVS Stock Plunges as Medicare Advantage Costs Spike

CVS Health Corporation (NYSE:CVS ) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants Karen Lynch - President, Chief Executive Officer Tom Cowhey - Chief Financial Officer David Falkowski - Executive Vice President, Chief Compliance Officer Brian Kane - Executive Vice President, President, Aetna Mike Pykosz - Executive Vice President, President of Health Care Delivery Larry McGrath - Senior Vice President of Business Development, Investor Relations Conference Call Participants Justin Lake - Wolfe Research Lisa Gill - J.P. Morgan Nathan Rich - Goldman Sachs Stephen Baxter - Wells Fargo Michael Cherny - Leerink Partners Josh Raskin - Nephron Research Elizabeth Anderson - Evercore ISI Ann Hynes - Mizuho Securities Operator Hello and welcome to today's CVS Health Q1 2024 Earnings Conference Call.

CVS Health Corporation (CVS) Q1 2024 Earnings Call Transcript

The shares of CVS Health Corp (NYSE:CVS) are plummeting today, down 18% at $55.55 at last glance and earlier as low as $54.04.

News for CVS Health Stock (CVS)